

## New Zealand standardised oral formulation batch sheet

# Levothyroxine suspension 15 microgram/mL (80 mL)

NB: Please check strength as there are two

Patient's name		Storage condition		In a refrigerator			At room temperature		
NHI	11		Temperature		2-8°C			≤ 25°C	
Date compounded	pounded		Shelf life		14 days			7 days	
Batch number		Recommended storage					May be stored at room temperature if this is more practical and temperatures greater than 25°C are avoided		
Ingredients required	and formula:								
Ingredient	Supplier	Batch number	Expiry date	Standard formula		Quantity dispensed	Di by	ispensed /	Checked by
Levothyroxine 100 microgram tablets				12 tablets					
Ora-Blend®	Perrigo			to	80 mL				
OR									
Ora-Plus®	Perrigo				40 mL				
Ora-Sweet®	Perrigo				40 mL				
Ora-Blend SF® or Ora	a-Sweet SF® (sug	gar free) can l	be substituted	?	Yes				
Calculations performed by									
Calculations checked by (pharmacist)									
Area cleared for processing by									
Instructions to comp	ound suspensio	n:							
	® unavailable: P		ra-Plus® and O	ra-Sv	veet® to	form the dilu	uent	t.	
2. Crush tablets	s in mortar to a	fine powder.							
3. Add diluent (	(Ora-Blend® or p	orepared dilu	ent) to form a	smoc	th paste	<b>e</b> .			
4. Gradually ad	d the diluent an	d transfer to	the final meas	uring	flask, ri	nsing the mo	rtar	well. Mix	well.
5. Make up to the final volume and mix well.									
6. Label and pa	ckage product a	ppropriately							
Labels									
Attach product label	and auxiliary la	bels:						Label	checked by



### New Zealand standardised oral formulation batch sheet

## Levothyroxine suspension 15 microgram/mL (80 mL)

NB: Please check strength as there are two

Final yield	mL	Checked by				
Final appearance of product	Pale white suspension.					
Container	Amber plastic mission bottle.					
Compounded by	Name:	ignature:	Date:			
Final check and product release	Name:	ignature:	Date:			
<ol> <li>Special instructions:         <ol> <li>Shake well before use.</li> <li>Store in a refrigerator.</li> <li>Synthroid® 25 microgram tablets may be crushed if appropriate - see notes in the New Zealand Formulary for Children (NZFC).</li> </ol> </li> </ol>						

#### References:

- 1. Nahata MC. Int J Pharm Compd, 2015; 19(5): 428-431.
- 2. Nahata MC, Pai V, *Paediatric drug formulations*. 2011, Cincinnati, OH: Harvey Whitney Books.

Prepared by	New Zealand Compounding Working Group					
Approved by	Medication Safety Expert Advisory Group of Health Quality and Safety Commission NZ					
Hosted by	Pharmaceutical Society of New Zealand  Standard Formulations in the Practice Support section of the PSNZ website					
Version number	2.0	Version approval date	17/07/19			
Document review due	01/08/21					

Disclaimer: this batch sheet has been designed to provide guidance and standardised formulations for New Zealand pharmacists. Please read and familiarise yourself with the general guidance for compounding oral liquids (available on the PSNZ web site) before use. Information was considered accurate at the time of publication.